1 Study Coverage
    1.1 Genome-Based Drug Product Introduction
    1.2 Market by Type
        1.2.1 Global Genome-Based Drug Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
        1.2.2 Insulin
        1.2.3 Growth Hormone
        1.2.4 Monoclonal Antibody
        1.2.5 Other
    1.3 Market by Application
        1.3.1 Global Genome-Based Drug Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
        1.3.2 Hospital
        1.3.3 Pharmaceutical Factory
        1.3.4 Other
    1.4 Study Objectives
    1.5 Years Considered
2 Executive Summary
    2.1 Global Genome-Based Drug Sales Estimates and Forecasts 2017-2028
    2.2 Global Genome-Based Drug Revenue Estimates and Forecasts 2017-2028
    2.3 Global Genome-Based Drug Revenue by Region: 2017 VS 2021 VS 2028
    2.4 Global Genome-Based Drug Sales by Region
        2.4.1 Global Genome-Based Drug Sales by Region (2017-2022)
        2.4.2 Global Sales Genome-Based Drug by Region (2023-2028)
    2.5 Global Genome-Based Drug Revenue by Region
        2.5.1 Global Genome-Based Drug Revenue by Region (2017-2022)
        2.5.2 Global Genome-Based Drug Revenue by Region (2023-2028)
    2.6 North America
    2.7 Europe
    2.8 Asia-Pacific
    2.9 Latin America
    2.10 Middle East & Africa
3 Competition by Manufacturers
    3.1 Global Genome-Based Drug Sales by Manufacturers
        3.1.1 Global Top Genome-Based Drug Manufacturers by Sales (2017-2022)
        3.1.2 Global Genome-Based Drug Sales Market Share by Manufacturers (2017-2022)
        3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Genome-Based Drug in 2021
    3.2 Global Genome-Based Drug Revenue by Manufacturers
        3.2.1 Global Genome-Based Drug Revenue by Manufacturers (2017-2022)
        3.2.2 Global Genome-Based Drug Revenue Market Share by Manufacturers (2017-2022)
        3.2.3 Global Top 10 and Top 5 Companies by Genome-Based Drug Revenue in 2021
    3.3 Global Genome-Based Drug Sales Price by Manufacturers (2017-2022)
    3.4 Analysis of Competitive Landscape
        3.4.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
        3.4.2 Global Genome-Based Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
        3.4.3 Global Genome-Based Drug Manufacturers Geographical Distribution
    3.5 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
    4.1 Global Genome-Based Drug Sales by Type
        4.1.1 Global Genome-Based Drug Historical Sales by Type (2017-2022)
        4.1.2 Global Genome-Based Drug Forecasted Sales by Type (2023-2028)
        4.1.3 Global Genome-Based Drug Sales Market Share by Type (2017-2028)
    4.2 Global Genome-Based Drug Revenue by Type
        4.2.1 Global Genome-Based Drug Historical Revenue by Type (2017-2022)
        4.2.2 Global Genome-Based Drug Forecasted Revenue by Type (2023-2028)
        4.2.3 Global Genome-Based Drug Revenue Market Share by Type (2017-2028)
    4.3 Global Genome-Based Drug Price by Type
        4.3.1 Global Genome-Based Drug Price by Type (2017-2022)
        4.3.2 Global Genome-Based Drug Price Forecast by Type (2023-2028)
5 Market Size by Application
    5.1 Global Genome-Based Drug Sales by Application
        5.1.1 Global Genome-Based Drug Historical Sales by Application (2017-2022)
        5.1.2 Global Genome-Based Drug Forecasted Sales by Application (2023-2028)
        5.1.3 Global Genome-Based Drug Sales Market Share by Application (2017-2028)
    5.2 Global Genome-Based Drug Revenue by Application
        5.2.1 Global Genome-Based Drug Historical Revenue by Application (2017-2022)
        5.2.2 Global Genome-Based Drug Forecasted Revenue by Application (2023-2028)
        5.2.3 Global Genome-Based Drug Revenue Market Share by Application (2017-2028)
    5.3 Global Genome-Based Drug Price by Application
        5.3.1 Global Genome-Based Drug Price by Application (2017-2022)
        5.3.2 Global Genome-Based Drug Price Forecast by Application (2023-2028)
6 North America
    6.1 North America Genome-Based Drug Market Size by Type
        6.1.1 North America Genome-Based Drug Sales by Type (2017-2028)
        6.1.2 North America Genome-Based Drug Revenue by Type (2017-2028)
    6.2 North America Genome-Based Drug Market Size by Application
        6.2.1 North America Genome-Based Drug Sales by Application (2017-2028)
        6.2.2 North America Genome-Based Drug Revenue by Application (2017-2028)
    6.3 North America Genome-Based Drug Market Size by Country
        6.3.1 North America Genome-Based Drug Sales by Country (2017-2028)
        6.3.2 North America Genome-Based Drug Revenue by Country (2017-2028)
        6.3.3 U.S.
        6.3.4 Canada
7 Europe
    7.1 Europe Genome-Based Drug Market Size by Type
        7.1.1 Europe Genome-Based Drug Sales by Type (2017-2028)
        7.1.2 Europe Genome-Based Drug Revenue by Type (2017-2028)
    7.2 Europe Genome-Based Drug Market Size by Application
        7.2.1 Europe Genome-Based Drug Sales by Application (2017-2028)
        7.2.2 Europe Genome-Based Drug Revenue by Application (2017-2028)
    7.3 Europe Genome-Based Drug Market Size by Country
        7.3.1 Europe Genome-Based Drug Sales by Country (2017-2028)
        7.3.2 Europe Genome-Based Drug Revenue by Country (2017-2028)
        7.3.3 Germany
        7.3.4 France
        7.3.5 U.K.
        7.3.6 Italy
        7.3.7 Russia
8 Asia Pacific
    8.1 Asia Pacific Genome-Based Drug Market Size by Type
        8.1.1 Asia Pacific Genome-Based Drug Sales by Type (2017-2028)
        8.1.2 Asia Pacific Genome-Based Drug Revenue by Type (2017-2028)
    8.2 Asia Pacific Genome-Based Drug Market Size by Application
        8.2.1 Asia Pacific Genome-Based Drug Sales by Application (2017-2028)
        8.2.2 Asia Pacific Genome-Based Drug Revenue by Application (2017-2028)
    8.3 Asia Pacific Genome-Based Drug Market Size by Region
        8.3.1 Asia Pacific Genome-Based Drug Sales by Region (2017-2028)
        8.3.2 Asia Pacific Genome-Based Drug Revenue by Region (2017-2028)
        8.3.3 China
        8.3.4 Japan
        8.3.5 South Korea
        8.3.6 India
        8.3.7 Australia
        8.3.8 Taiwan
        8.3.9 Indonesia
        8.3.10 Thailand
        8.3.11 Malaysia
        8.3.12 Philippines
9 Latin America
    9.1 Latin America Genome-Based Drug Market Size by Type
        9.1.1 Latin America Genome-Based Drug Sales by Type (2017-2028)
        9.1.2 Latin America Genome-Based Drug Revenue by Type (2017-2028)
    9.2 Latin America Genome-Based Drug Market Size by Application
        9.2.1 Latin America Genome-Based Drug Sales by Application (2017-2028)
        9.2.2 Latin America Genome-Based Drug Revenue by Application (2017-2028)
    9.3 Latin America Genome-Based Drug Market Size by Country
        9.3.1 Latin America Genome-Based Drug Sales by Country (2017-2028)
        9.3.2 Latin America Genome-Based Drug Revenue by Country (2017-2028)
        9.3.3 Mexico
        9.3.4 Brazil
        9.3.5 Argentina
10 Middle East and Africa
    10.1 Middle East and Africa Genome-Based Drug Market Size by Type
        10.1.1 Middle East and Africa Genome-Based Drug Sales by Type (2017-2028)
        10.1.2 Middle East and Africa Genome-Based Drug Revenue by Type (2017-2028)
    10.2 Middle East and Africa Genome-Based Drug Market Size by Application
        10.2.1 Middle East and Africa Genome-Based Drug Sales by Application (2017-2028)
        10.2.2 Middle East and Africa Genome-Based Drug Revenue by Application (2017-2028)
    10.3 Middle East and Africa Genome-Based Drug Market Size by Country
        10.3.1 Middle East and Africa Genome-Based Drug Sales by Country (2017-2028)
        10.3.2 Middle East and Africa Genome-Based Drug Revenue by Country (2017-2028)
        10.3.3 Turkey
        10.3.4 Saudi Arabia
11 Company Profiles
    11.1 Sandoz International
        11.1.1 Sandoz International Corporation Information
        11.1.2 Sandoz International Overview
        11.1.3 Sandoz International Genome-Based Drug Sales, Price, Revenue and Gross Margin (2017-2022)
        11.1.4 Sandoz International Genome-Based Drug Product Model Numbers, Pictures, Descriptions and Specifications
        11.1.5 Sandoz International Recent Developments
    11.2 Teva pharmaceutical industries
        11.2.1 Teva pharmaceutical industries Corporation Information
        11.2.2 Teva pharmaceutical industries Overview
        11.2.3 Teva pharmaceutical industries Genome-Based Drug Sales, Price, Revenue and Gross Margin (2017-2022)
        11.2.4 Teva pharmaceutical industries Genome-Based Drug Product Model Numbers, Pictures, Descriptions and Specifications
        11.2.5 Teva pharmaceutical industries Recent Developments
    11.3 Mylan
        11.3.1 Mylan Corporation Information
        11.3.2 Mylan Overview
        11.3.3 Mylan Genome-Based Drug Sales, Price, Revenue and Gross Margin (2017-2022)
        11.3.4 Mylan Genome-Based Drug Product Model Numbers, Pictures, Descriptions and Specifications
        11.3.5 Mylan Recent Developments
    11.4 3SBio
        11.4.1 3SBio Corporation Information
        11.4.2 3SBio Overview
        11.4.3 3SBio Genome-Based Drug Sales, Price, Revenue and Gross Margin (2017-2022)
        11.4.4 3SBio Genome-Based Drug Product Model Numbers, Pictures, Descriptions and Specifications
        11.4.5 3SBio Recent Developments
    11.5 Shanghai Fosun Pharmaceutical
        11.5.1 Shanghai Fosun Pharmaceutical Corporation Information
        11.5.2 Shanghai Fosun Pharmaceutical Overview
        11.5.3 Shanghai Fosun Pharmaceutical Genome-Based Drug Sales, Price, Revenue and Gross Margin (2017-2022)
        11.5.4 Shanghai Fosun Pharmaceutical Genome-Based Drug Product Model Numbers, Pictures, Descriptions and Specifications
        11.5.5 Shanghai Fosun Pharmaceutical Recent Developments
    11.6 Tonghua Dongbao Pharmaceutical
        11.6.1 Tonghua Dongbao Pharmaceutical Corporation Information
        11.6.2 Tonghua Dongbao Pharmaceutical Overview
        11.6.3 Tonghua Dongbao Pharmaceutical Genome-Based Drug Sales, Price, Revenue and Gross Margin (2017-2022)
        11.6.4 Tonghua Dongbao Pharmaceutical Genome-Based Drug Product Model Numbers, Pictures, Descriptions and Specifications
        11.6.5 Tonghua Dongbao Pharmaceutical Recent Developments
    11.7 Biocon
        11.7.1 Biocon Corporation Information
        11.7.2 Biocon Overview
        11.7.3 Biocon Genome-Based Drug Sales, Price, Revenue and Gross Margin (2017-2022)
        11.7.4 Biocon Genome-Based Drug Product Model Numbers, Pictures, Descriptions and Specifications
        11.7.5 Biocon Recent Developments
    11.8 Reliance Life Sciences
        11.8.1 Reliance Life Sciences Corporation Information
        11.8.2 Reliance Life Sciences Overview
        11.8.3 Reliance Life Sciences Genome-Based Drug Sales, Price, Revenue and Gross Margin (2017-2022)
        11.8.4 Reliance Life Sciences Genome-Based Drug Product Model Numbers, Pictures, Descriptions and Specifications
        11.8.5 Reliance Life Sciences Recent Developments
    11.9 Probiomed
        11.9.1 Probiomed Corporation Information
        11.9.2 Probiomed Overview
        11.9.3 Probiomed Genome-Based Drug Sales, Price, Revenue and Gross Margin (2017-2022)
        11.9.4 Probiomed Genome-Based Drug Product Model Numbers, Pictures, Descriptions and Specifications
        11.9.5 Probiomed Recent Developments
    11.10 Biosidus
        11.10.1 Biosidus Corporation Information
        11.10.2 Biosidus Overview
        11.10.3 Biosidus Genome-Based Drug Sales, Price, Revenue and Gross Margin (2017-2022)
        11.10.4 Biosidus Genome-Based Drug Product Model Numbers, Pictures, Descriptions and Specifications
        11.10.5 Biosidus Recent Developments
    11.11 AMEGA Biotech
        11.11.1 AMEGA Biotech Corporation Information
        11.11.2 AMEGA Biotech Overview
        11.11.3 AMEGA Biotech Genome-Based Drug Sales, Price, Revenue and Gross Margin (2017-2022)
        11.11.4 AMEGA Biotech Genome-Based Drug Product Model Numbers, Pictures, Descriptions and Specifications
        11.11.5 AMEGA Biotech Recent Developments
    11.12 Celltrion
        11.12.1 Celltrion Corporation Information
        11.12.2 Celltrion Overview
        11.12.3 Celltrion Genome-Based Drug Sales, Price, Revenue and Gross Margin (2017-2022)
        11.12.4 Celltrion Genome-Based Drug Product Model Numbers, Pictures, Descriptions and Specifications
        11.12.5 Celltrion Recent Developments
    11.13 LG Life Science
        11.13.1 LG Life Science Corporation Information
        11.13.2 LG Life Science Overview
        11.13.3 LG Life Science Genome-Based Drug Sales, Price, Revenue and Gross Margin (2017-2022)
        11.13.4 LG Life Science Genome-Based Drug Product Model Numbers, Pictures, Descriptions and Specifications
        11.13.5 LG Life Science Recent Developments
    11.14 Dong-A Pharmaceutical
        11.14.1 Dong-A Pharmaceutical Corporation Information
        11.14.2 Dong-A Pharmaceutical Overview
        11.14.3 Dong-A Pharmaceutical Genome-Based Drug Sales, Price, Revenue and Gross Margin (2017-2022)
        11.14.4 Dong-A Pharmaceutical Genome-Based Drug Product Model Numbers, Pictures, Descriptions and Specifications
        11.14.5 Dong-A Pharmaceutical Recent Developments
12 Industry Chain and Sales Channels Analysis
    12.1 Genome-Based Drug Industry Chain Analysis
    12.2 Genome-Based Drug Key Raw Materials
        12.2.1 Key Raw Materials
        12.2.2 Raw Materials Key Suppliers
    12.3 Genome-Based Drug Production Mode & Process
    12.4 Genome-Based Drug Sales and Marketing
        12.4.1 Genome-Based Drug Sales Channels
        12.4.2 Genome-Based Drug Distributors
    12.5 Genome-Based Drug Customers
13 Market Drivers, Opportunities, Challenges and Risks Factors Analysis
    13.1 Genome-Based Drug Industry Trends
    13.2 Genome-Based Drug Market Drivers
    13.3 Genome-Based Drug Market Challenges
    13.4 Genome-Based Drug Market Restraints
14 Key Findings in The Global Genome-Based Drug Study
15 Appendix
    15.1 Research Methodology
        15.1.1 Methodology/Research Approach
        15.1.2 Data Source
    15.2 Author Details
    15.3 Disclaimer
                  
              

                

                 
List of Tables
    Table 1. Global Genome-Based Drug Market Size Growth Rate by Type, 2017 VS 2021 VS 2028 (US$ Million)
    Table 2. Major Manufacturers of Insulin
    Table 3. Major Manufacturers of Growth Hormone
    Table 4. Major Manufacturers of Monoclonal Antibody
    Table 5. Major Manufacturers of Other
    Table 6. Global Genome-Based Drug Market Size Growth Rate by Application, 2017 VS 2021 VS 2028 (US$ Million)
    Table 7. Global Genome-Based Drug Revenue by Region: 2017 VS 2021 VS 2028 (US$ Million)
    Table 8. Global Genome-Based Drug Sales by Region (2017-2022) & (Kiloton)
    Table 9. Global Genome-Based Drug Sales Market Share by Region (2017-2022)
    Table 10. Global Genome-Based Drug Sales by Region (2023-2028) & (Kiloton)
    Table 11. Global Genome-Based Drug Sales Market Share by Region (2023-2028)
    Table 12. Global Genome-Based Drug Revenue by Region (2017-2022) & (US$ Million)
    Table 13. Global Genome-Based Drug Revenue Market Share by Region (2017-2022)
    Table 14. Global Genome-Based Drug Revenue by Region (2023-2028) & (US$ Million)
    Table 15. Global Genome-Based Drug Revenue Market Share by Region (2023-2028)
    Table 16. Global Genome-Based Drug Sales by Manufacturers (2017-2022) & (Kiloton)
    Table 17. Global Genome-Based Drug Sales Share by Manufacturers (2017-2022)
    Table 18. Global Genome-Based Drug Revenue by Manufacturers (2017-2022) & (US$ Million)
    Table 19. Global Genome-Based Drug Revenue Share by Manufacturers (2017-2022)
    Table 20. Genome-Based Drug Price by Manufacturers (2017-2022) &(US$/Ton)
    Table 21. Global Genome-Based Drug Manufacturers Market Concentration Ratio (CR5 and HHI)
    Table 22. Global Genome-Based Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Genome-Based Drug as of 2021)
    Table 23. Genome-Based Drug Manufacturing Base Distribution and Headquarters
    Table 24. Manufacturers Genome-Based Drug Product Offered
    Table 25. Date of Manufacturers Enter into Genome-Based Drug Market
    Table 26. Mergers & Acquisitions, Expansion Plans
    Table 27. Global Genome-Based Drug Sales by Type (2017-2022) & (Kiloton)
    Table 28. Global Genome-Based Drug Sales by Type (2023-2028) & (Kiloton)
    Table 29. Global Genome-Based Drug Sales Share by Type (2017-2022)
    Table 30. Global Genome-Based Drug Sales Share by Type (2023-2028)
    Table 31. Global Genome-Based Drug Revenue by Type (2017-2022) & (US$ Million)
    Table 32. Global Genome-Based Drug Revenue by Type (2023-2028) & (US$ Million)
    Table 33. Global Genome-Based Drug Revenue Share by Type (2017-2022)
    Table 34. Global Genome-Based Drug Revenue Share by Type (2023-2028)
    Table 35. Genome-Based Drug Price by Type (2017-2022) & (US$/Ton)
    Table 36. Global Genome-Based Drug Price Forecast by Type (2023-2028) & (US$/Ton)
    Table 37. Global Genome-Based Drug Sales by Application (2017-2022) & (Kiloton)
    Table 38. Global Genome-Based Drug Sales by Application (2023-2028) & (Kiloton)
    Table 39. Global Genome-Based Drug Sales Share by Application (2017-2022)
    Table 40. Global Genome-Based Drug Sales Share by Application (2023-2028)
    Table 41. Global Genome-Based Drug Revenue by Application (2017-2022) & (US$ Million)
    Table 42. Global Genome-Based Drug Revenue by Application (2023-2028) & (US$ Million)
    Table 43. Global Genome-Based Drug Revenue Share by Application (2017-2022)
    Table 44. Global Genome-Based Drug Revenue Share by Application (2023-2028)
    Table 45. Genome-Based Drug Price by Application (2017-2022) & (US$/Ton)
    Table 46. Global Genome-Based Drug Price Forecast by Application (2023-2028) & (US$/Ton)
    Table 47. North America Genome-Based Drug Sales by Type (2017-2022) & (Kiloton)
    Table 48. North America Genome-Based Drug Sales by Type (2023-2028) & (Kiloton)
    Table 49. North America Genome-Based Drug Revenue by Type (2017-2022) & (US$ Million)
    Table 50. North America Genome-Based Drug Revenue by Type (2023-2028) & (US$ Million)
    Table 51. North America Genome-Based Drug Sales by Application (2017-2022) & (Kiloton)
    Table 52. North America Genome-Based Drug Sales by Application (2023-2028) & (Kiloton)
    Table 53. North America Genome-Based Drug Revenue by Application (2017-2022) & (US$ Million)
    Table 54. North America Genome-Based Drug Revenue by Application (2023-2028) & (US$ Million)
    Table 55. North America Genome-Based Drug Sales by Country (2017-2022) & (Kiloton)
    Table 56. North America Genome-Based Drug Sales by Country (2023-2028) & (Kiloton)
    Table 57. North America Genome-Based Drug Revenue by Country (2017-2022) & (US$ Million)
    Table 58. North America Genome-Based Drug Revenue by Country (2023-2028) & (US$ Million)
    Table 59. Europe Genome-Based Drug Sales by Type (2017-2022) & (Kiloton)
    Table 60. Europe Genome-Based Drug Sales by Type (2023-2028) & (Kiloton)
    Table 61. Europe Genome-Based Drug Revenue by Type (2017-2022) & (US$ Million)
    Table 62. Europe Genome-Based Drug Revenue by Type (2023-2028) & (US$ Million)
    Table 63. Europe Genome-Based Drug Sales by Application (2017-2022) & (Kiloton)
    Table 64. Europe Genome-Based Drug Sales by Application (2023-2028) & (Kiloton)
    Table 65. Europe Genome-Based Drug Revenue by Application (2017-2022) & (US$ Million)
    Table 66. Europe Genome-Based Drug Revenue by Application (2023-2028) & (US$ Million)
    Table 67. Europe Genome-Based Drug Sales by Country (2017-2022) & (Kiloton)
    Table 68. Europe Genome-Based Drug Sales by Country (2023-2028) & (Kiloton)
    Table 69. Europe Genome-Based Drug Revenue by Country (2017-2022) & (US$ Million)
    Table 70. Europe Genome-Based Drug Revenue by Country (2023-2028) & (US$ Million)
    Table 71. Asia Pacific Genome-Based Drug Sales by Type (2017-2022) & (Kiloton)
    Table 72. Asia Pacific Genome-Based Drug Sales by Type (2023-2028) & (Kiloton)
    Table 73. Asia Pacific Genome-Based Drug Revenue by Type (2017-2022) & (US$ Million)
    Table 74. Asia Pacific Genome-Based Drug Revenue by Type (2023-2028) & (US$ Million)
    Table 75. Asia Pacific Genome-Based Drug Sales by Application (2017-2022) & (Kiloton)
    Table 76. Asia Pacific Genome-Based Drug Sales by Application (2023-2028) & (Kiloton)
    Table 77. Asia Pacific Genome-Based Drug Revenue by Application (2017-2022) & (US$ Million)
    Table 78. Asia Pacific Genome-Based Drug Revenue by Application (2023-2028) & (US$ Million)
    Table 79. Asia Pacific Genome-Based Drug Sales by Region (2017-2022) & (Kiloton)
    Table 80. Asia Pacific Genome-Based Drug Sales by Region (2023-2028) & (Kiloton)
    Table 81. Asia Pacific Genome-Based Drug Revenue by Region (2017-2022) & (US$ Million)
    Table 82. Asia Pacific Genome-Based Drug Revenue by Region (2023-2028) & (US$ Million)
    Table 83. Latin America Genome-Based Drug Sales by Type (2017-2022) & (Kiloton)
    Table 84. Latin America Genome-Based Drug Sales by Type (2023-2028) & (Kiloton)
    Table 85. Latin America Genome-Based Drug Revenue by Type (2017-2022) & (US$ Million)
    Table 86. Latin America Genome-Based Drug Revenue by Type (2023-2028) & (US$ Million)
    Table 87. Latin America Genome-Based Drug Sales by Application (2017-2022) & (Kiloton)
    Table 88. Latin America Genome-Based Drug Sales by Application (2023-2028) & (Kiloton)
    Table 89. Latin America Genome-Based Drug Revenue by Application (2017-2022) & (US$ Million)
    Table 90. Latin America Genome-Based Drug Revenue by Application (2023-2028) & (US$ Million)
    Table 91. Latin America Genome-Based Drug Sales by Country (2017-2022) & (Kiloton)
    Table 92. Latin America Genome-Based Drug Sales by Country (2023-2028) & (Kiloton)
    Table 93. Latin America Genome-Based Drug Revenue by Country (2017-2022) & (US$ Million)
    Table 94. Latin America Genome-Based Drug Revenue by Country (2023-2028) & (US$ Million)
    Table 95. Middle East and Africa Genome-Based Drug Sales by Type (2017-2022) & (Kiloton)
    Table 96. Middle East and Africa Genome-Based Drug Sales by Type (2023-2028) & (Kiloton)
    Table 97. Middle East and Africa Genome-Based Drug Revenue by Type (2017-2022) & (US$ Million)
    Table 98. Middle East and Africa Genome-Based Drug Revenue by Type (2023-2028) & (US$ Million)
    Table 99. Middle East and Africa Genome-Based Drug Sales by Application (2017-2022) & (Kiloton)
    Table 100. Middle East and Africa Genome-Based Drug Sales by Application (2023-2028) & (Kiloton)
    Table 101. Middle East and Africa Genome-Based Drug Revenue by Application (2017-2022) & (US$ Million)
    Table 102. Middle East and Africa Genome-Based Drug Revenue by Application (2023-2028) & (US$ Million)
    Table 103. Middle East and Africa Genome-Based Drug Sales by Country (2017-2022) & (Kiloton)
    Table 104. Middle East and Africa Genome-Based Drug Sales by Country (2023-2028) & (Kiloton)
    Table 105. Middle East and Africa Genome-Based Drug Revenue by Country (2017-2022) & (US$ Million)
    Table 106. Middle East and Africa Genome-Based Drug Revenue by Country (2023-2028) & (US$ Million)
    Table 107. Sandoz International Corporation Information
    Table 108. Sandoz International Description and Major Businesses
    Table 109. Sandoz International Genome-Based Drug Sales (Kiloton), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2017-2022)
    Table 110. Sandoz International Genome-Based Drug Product Model Numbers, Pictures, Descriptions and Specifications
    Table 111. Sandoz International Recent Developments
    Table 112. Teva pharmaceutical industries Corporation Information
    Table 113. Teva pharmaceutical industries Description and Major Businesses
    Table 114. Teva pharmaceutical industries Genome-Based Drug Sales (Kiloton), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2017-2022)
    Table 115. Teva pharmaceutical industries Genome-Based Drug Product Model Numbers, Pictures, Descriptions and Specifications
    Table 116. Teva pharmaceutical industries Recent Developments
    Table 117. Mylan Corporation Information
    Table 118. Mylan Description and Major Businesses
    Table 119. Mylan Genome-Based Drug Sales (Kiloton), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2017-2022)
    Table 120. Mylan Genome-Based Drug Product Model Numbers, Pictures, Descriptions and Specifications
    Table 121. Mylan Recent Developments
    Table 122. 3SBio Corporation Information
    Table 123. 3SBio Description and Major Businesses
    Table 124. 3SBio Genome-Based Drug Sales (Kiloton), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2017-2022)
    Table 125. 3SBio Genome-Based Drug Product Model Numbers, Pictures, Descriptions and Specifications
    Table 126. 3SBio Recent Developments
    Table 127. Shanghai Fosun Pharmaceutical Corporation Information
    Table 128. Shanghai Fosun Pharmaceutical Description and Major Businesses
    Table 129. Shanghai Fosun Pharmaceutical Genome-Based Drug Sales (Kiloton), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2017-2022)
    Table 130. Shanghai Fosun Pharmaceutical Genome-Based Drug Product Model Numbers, Pictures, Descriptions and Specifications
    Table 131. Shanghai Fosun Pharmaceutical Recent Developments
    Table 132. Tonghua Dongbao Pharmaceutical Corporation Information
    Table 133. Tonghua Dongbao Pharmaceutical Description and Major Businesses
    Table 134. Tonghua Dongbao Pharmaceutical Genome-Based Drug Sales (Kiloton), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2017-2022)
    Table 135. Tonghua Dongbao Pharmaceutical Genome-Based Drug Product Model Numbers, Pictures, Descriptions and Specifications
    Table 136. Tonghua Dongbao Pharmaceutical Recent Developments
    Table 137. Biocon Corporation Information
    Table 138. Biocon Description and Major Businesses
    Table 139. Biocon Genome-Based Drug Sales (Kiloton), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2017-2022)
    Table 140. Biocon Genome-Based Drug Product Model Numbers, Pictures, Descriptions and Specifications
    Table 141. Biocon Recent Developments
    Table 142. Reliance Life Sciences Corporation Information
    Table 143. Reliance Life Sciences Description and Major Businesses
    Table 144. Reliance Life Sciences Genome-Based Drug Sales (Kiloton), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2017-2022)
    Table 145. Reliance Life Sciences Genome-Based Drug Product Model Numbers, Pictures, Descriptions and Specifications
    Table 146. Reliance Life Sciences Recent Developments
    Table 147. Probiomed Corporation Information
    Table 148. Probiomed Description and Major Businesses
    Table 149. Probiomed Genome-Based Drug Sales (Kiloton), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2017-2022)
    Table 150. Probiomed Genome-Based Drug Product Model Numbers, Pictures, Descriptions and Specifications
    Table 151. Probiomed Recent Developments
    Table 152. Biosidus Corporation Information
    Table 153. Biosidus Description and Major Businesses
    Table 154. Biosidus Genome-Based Drug Sales (Kiloton), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2017-2022)
    Table 155. Biosidus Genome-Based Drug Product Model Numbers, Pictures, Descriptions and Specifications
    Table 156. Biosidus Recent Developments
    Table 157. AMEGA Biotech Corporation Information
    Table 158. AMEGA Biotech Description and Major Businesses
    Table 159. AMEGA Biotech Genome-Based Drug Sales (Kiloton), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2017-2022)
    Table 160. AMEGA Biotech Genome-Based Drug Product Model Numbers, Pictures, Descriptions and Specifications
    Table 161. AMEGA Biotech Recent Developments
    Table 162. Celltrion Corporation Information
    Table 163. Celltrion Description and Major Businesses
    Table 164. Celltrion Genome-Based Drug Sales (Kiloton), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2017-2022)
    Table 165. Celltrion Genome-Based Drug Product Model Numbers, Pictures, Descriptions and Specifications
    Table 166. Celltrion Recent Developments
    Table 167. LG Life Science Corporation Information
    Table 168. LG Life Science Description and Major Businesses
    Table 169. LG Life Science Genome-Based Drug Sales (Kiloton), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2017-2022)
    Table 170. LG Life Science Genome-Based Drug Product Model Numbers, Pictures, Descriptions and Specifications
    Table 171. LG Life Science Recent Developments
    Table 172. Dong-A Pharmaceutical Corporation Information
    Table 173. Dong-A Pharmaceutical Description and Major Businesses
    Table 174. Dong-A Pharmaceutical Genome-Based Drug Sales (Kiloton), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2017-2022)
    Table 175. Dong-A Pharmaceutical Genome-Based Drug Product Model Numbers, Pictures, Descriptions and Specifications
    Table 176. Dong-A Pharmaceutical Recent Developments
    Table 177. Key Raw Materials Lists
    Table 178. Raw Materials Key Suppliers Lists
    Table 179. Genome-Based Drug Distributors List
    Table 180. Genome-Based Drug Customers List
    Table 181. Genome-Based Drug Market Trends
    Table 182. Genome-Based Drug Market Drivers
    Table 183. Genome-Based Drug Market Challenges
    Table 184. Genome-Based Drug Market Restraints
    Table 185. Research Programs/Design for This Report
    Table 186. Key Data Information from Secondary Sources
    Table 187. Key Data Information from Primary Sources
List of Figures
    Figure 1. Genome-Based Drug Product Picture
    Figure 3. Global Genome-Based Drug Market Share by Type in 2021 & 2028
    Figure 3. Insulin Product Picture
    Figure 4. Growth Hormone Product Picture
    Figure 5. Monoclonal Antibody Product Picture
    Figure 6. Other Product Picture
    Figure 7. Global Genome-Based Drug Market Share by Application in 2021 & 2028
    Figure 8. Hospital
    Figure 9. Pharmaceutical Factory
    Figure 10. Other
    Figure 11. Genome-Based Drug Report Years Considered
    Figure 12. Global Genome-Based Drug Sales 2017-2028 (Kiloton)
    Figure 13. Global Genome-Based Drug Revenue, (US$ Million), 2017 VS 2021 VS 2028
    Figure 14. Global Genome-Based Drug Revenue 2017-2028 (US$ Million)
    Figure 15. Global Genome-Based Drug Revenue Market Share by Region in Percentage: 2021 Versus 2028
    Figure 16. Global Genome-Based Drug Sales Market Share by Region (2017-2022)
    Figure 17. Global Genome-Based Drug Sales Market Share by Region (2023-2028)
    Figure 18. North America Genome-Based Drug Sales YoY (2017-2028) & (Kiloton)
    Figure 19. North America Genome-Based Drug Revenue YoY (2017-2028) & (US$ Million)
    Figure 20. Europe Genome-Based Drug Sales YoY (2017-2028) & (Kiloton)
    Figure 21. Europe Genome-Based Drug Revenue YoY (2017-2028) & (US$ Million)
    Figure 22. Asia-Pacific Genome-Based Drug Sales YoY (2017-2028) & (Kiloton)
    Figure 23. Asia-Pacific Genome-Based Drug Revenue YoY (2017-2028) & (US$ Million)
    Figure 24. Latin America Genome-Based Drug Sales YoY (2017-2028) & (Kiloton)
    Figure 25. Latin America Genome-Based Drug Revenue YoY (2017-2028) & (US$ Million)
    Figure 26. Middle East & Africa Genome-Based Drug Sales YoY (2017-2028) & (Kiloton)
    Figure 27. Middle East & Africa Genome-Based Drug Revenue YoY (2017-2028) & (US$ Million)
    Figure 28. The Genome-Based Drug Market Share of Top 10 and Top 5 Largest Manufacturers Around the World in 2021
    Figure 29. The Top 5 and 10 Largest Manufacturers of Genome-Based Drug in the World: Market Share by Genome-Based Drug Revenue in 2021
    Figure 30. Global Genome-Based Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2017 VS 2021
    Figure 31. Global Genome-Based Drug Sales Market Share by Type (2017-2028)
    Figure 32. Global Genome-Based Drug Revenue Market Share by Type (2017-2028)
    Figure 33. Global Genome-Based Drug Sales Market Share by Application (2017-2028)
    Figure 34. Global Genome-Based Drug Revenue Market Share by Application (2017-2028)
    Figure 35. North America Genome-Based Drug Sales Market Share by Type (2017-2028)
    Figure 36. North America Genome-Based Drug Revenue Market Share by Type (2017-2028)
    Figure 37. North America Genome-Based Drug Sales Market Share by Application (2017-2028)
    Figure 38. North America Genome-Based Drug Revenue Market Share by Application (2017-2028)
    Figure 39. North America Genome-Based Drug Sales Share by Country (2017-2028)
    Figure 40. North America Genome-Based Drug Revenue Share by Country (2017-2028)
    Figure 41. U.S. Genome-Based Drug Revenue (2017-2028) & (US$ Million)
    Figure 42. Canada Genome-Based Drug Revenue (2017-2028) & (US$ Million)
    Figure 43. Europe Genome-Based Drug Sales Market Share by Type (2017-2028)
    Figure 44. Europe Genome-Based Drug Revenue Market Share by Type (2017-2028)
    Figure 45. Europe Genome-Based Drug Sales Market Share by Application (2017-2028)
    Figure 46. Europe Genome-Based Drug Revenue Market Share by Application (2017-2028)
    Figure 47. Europe Genome-Based Drug Sales Share by Country (2017-2028)
    Figure 48. Europe Genome-Based Drug Revenue Share by Country (2017-2028)
    Figure 49. Germany Genome-Based Drug Revenue (2017-2028) & (US$ Million)
    Figure 50. France Genome-Based Drug Revenue (2017-2028) & (US$ Million)
    Figure 51. U.K. Genome-Based Drug Revenue (2017-2028) & (US$ Million)
    Figure 52. Italy Genome-Based Drug Revenue (2017-2028) & (US$ Million)
    Figure 53. Russia Genome-Based Drug Revenue (2017-2028) & (US$ Million)
    Figure 54. Asia Pacific Genome-Based Drug Sales Market Share by Type (2017-2028)
    Figure 55. Asia Pacific Genome-Based Drug Revenue Market Share by Type (2017-2028)
    Figure 56. Asia Pacific Genome-Based Drug Sales Market Share by Application (2017-2028)
    Figure 57. Asia Pacific Genome-Based Drug Revenue Market Share by Application (2017-2028)
    Figure 58. Asia Pacific Genome-Based Drug Sales Share by Region (2017-2028)
    Figure 59. Asia Pacific Genome-Based Drug Revenue Share by Region (2017-2028)
    Figure 60. China Genome-Based Drug Revenue (2017-2028) & (US$ Million)
    Figure 61. Japan Genome-Based Drug Revenue (2017-2028) & (US$ Million)
    Figure 62. South Korea Genome-Based Drug Revenue (2017-2028) & (US$ Million)
    Figure 63. India Genome-Based Drug Revenue (2017-2028) & (US$ Million)
    Figure 64. Australia Genome-Based Drug Revenue (2017-2028) & (US$ Million)
    Figure 65. Taiwan Genome-Based Drug Revenue (2017-2028) & (US$ Million)
    Figure 66. Indonesia Genome-Based Drug Revenue (2017-2028) & (US$ Million)
    Figure 67. Thailand Genome-Based Drug Revenue (2017-2028) & (US$ Million)
    Figure 68. Malaysia Genome-Based Drug Revenue (2017-2028) & (US$ Million)
    Figure 69. Philippines Genome-Based Drug Revenue (2017-2028) & (US$ Million)
    Figure 70. Latin America Genome-Based Drug Sales Market Share by Type (2017-2028)
    Figure 71. Latin America Genome-Based Drug Revenue Market Share by Type (2017-2028)
    Figure 72. Latin America Genome-Based Drug Sales Market Share by Application (2017-2028)
    Figure 73. Latin America Genome-Based Drug Revenue Market Share by Application (2017-2028)
    Figure 74. Latin America Genome-Based Drug Sales Share by Country (2017-2028)
    Figure 75. Latin America Genome-Based Drug Revenue Share by Country (2017-2028)
    Figure 76. Mexico Genome-Based Drug Revenue (2017-2028) & (US$ Million)
    Figure 77. Brazil Genome-Based Drug Revenue (2017-2028) & (US$ Million)
    Figure 78. Argentina Genome-Based Drug Revenue (2017-2028) & (US$ Million)
    Figure 79. Middle East and Africa Genome-Based Drug Sales Market Share by Type (2017-2028)
    Figure 80. Middle East and Africa Genome-Based Drug Revenue Market Share by Type (2017-2028)
    Figure 81. Middle East and Africa Genome-Based Drug Sales Market Share by Application (2017-2028)
    Figure 82. Middle East and Africa Genome-Based Drug Revenue Market Share by Application (2017-2028)
    Figure 83. Middle East and Africa Genome-Based Drug Sales Share by Country (2017-2028)
    Figure 84. Middle East and Africa Genome-Based Drug Revenue Share by Country (2017-2028)
    Figure 85. Turkey Genome-Based Drug Revenue (2017-2028) & (US$ Million)
    Figure 86. Saudi Arabia Genome-Based Drug Revenue (2017-2028) & (US$ Million)
    Figure 87. UAE Genome-Based Drug Revenue (2017-2028) & (US$ Million)
    Figure 88. Genome-Based Drug Value Chain
    Figure 89. Genome-Based Drug Production Process
    Figure 90. Channels of Distribution
    Figure 91. Distributors Profiles
    Figure 92. Bottom-up and Top-down Approaches for This Report
    Figure 93. Data Triangulation
    Figure 94. Key Executives Interviewed